Literature DB >> 32400071

Pedunculopontine Nucleus Microstructure Predicts Postural and Gait Symptoms in Parkinson's Disease.

Chesney E Craig1, Ned J Jenkinson2, John-Stuart Brittain3, Michel J Grothe4,5, Lynn Rochester6, Monty Silverdale7, Ana T D L Alho8,9, Eduardo J L Alho8, Paul S Holmes1, Nicola J Ray1.   

Abstract

BACKGROUND: There is an urgent need to identify individuals at risk of postural instability and gait difficulties, and the resulting propensity for falls, in Parkinson's disease.
OBJECTIVES: Given known relationships between posture and gait and degeneration of the cholinergic pedunculopontine nucleus, we investigated whether metrics of pedunculopontine nucleus microstructural integrity hold independent utility for predicting future postural instability and gait difficulties and whether they could be combined with other candidate biomarkers to improve prognostication of these symptoms.
METHODS: We used stereotactic mapping of the pedunculopontine nucleus and diffusion tensor imaging to extract baseline pedunculopontine nucleus diffusivity metrics in 147 participants with Parkinson's disease and 65 controls enrolled in the Parkinson's Progression Markers Initiative. We also recorded known candidate markers of posture and gait changes: loss of caudate dopamine and CSF β-amyloid 1-42 levels at baseline; as well as longitudinal progression motor symptoms over 72-months.
RESULTS: Survival analyses revealed that reduced dopamine in the caudate and increased axial diffusivity in the pedunculopontine nucleus incurred independent risk of postural instability and gait difficulties. Binary logistic regression and receiver operating characteristics analysis in 117 participants with complete follow-up data at 60 months revealed that only pedunculopontine nucleus microstructure provided more accurate discriminative ability for predicting future postural instability and gait difficulties than clinical and demographic variables alone.
CONCLUSION: Dopaminergic and cholinergic loss incur independent risk for future postural instability and gait difficulties, and pedunculopontine nucleus microstructure can be used to prognosticate these symptoms from early Parkinson's disease stages.
© 2020 The Authors. Movement Disorders published by Wiley Periodicals, Inc. on behalf of International Parkinson and Movement Disorder Society. © 2020 The Authors. Movement Disorders published by Wiley Periodicals, Inc. on behalf of International Parkinson and Movement Disorder Society.

Entities:  

Keywords:  Parkinson's disease; Pedunculopontine nucleus; Postural instability and gait difficulties; prognostic markers

Mesh:

Year:  2020        PMID: 32400071     DOI: 10.1002/mds.28051

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  10 in total

Review 1.  Cholinergic systems, attentional-motor integration, and cognitive control in Parkinson's disease.

Authors:  Roger L Albin; Sygrid van der Zee; Teus van Laar; Martin Sarter; Cindy Lustig; Martijn L T M Muller; Nicolaas I Bohnen
Journal:  Prog Brain Res       Date:  2022-02-04       Impact factor: 2.453

Review 2.  The Cholinergic Brain in Parkinson's Disease.

Authors:  Jacopo Pasquini; David J Brooks; Nicola Pavese
Journal:  Mov Disord Clin Pract       Date:  2021-08-23

3.  Static postural stability and neuropsychological performance after awakening from REM and NREM sleep in patients with chronic insomnia: a randomized, crossover, overnight polysomnography study.

Authors:  Wei-Chih Yeh; Yao-Chung Chuang; Chen-Wen Yen; Ming-Chung Liu; Meng-Ni Wu; Li-Min Liou; Cheng-Fang Hsieh; Ching-Fang Chien; Chung-Yao Hsu
Journal:  J Clin Sleep Med       Date:  2022-08-01       Impact factor: 4.324

4.  New Developments in Cholinergic Imaging in Alzheimer and Lewy Body Disorders.

Authors:  Chesney E Craig; Nicola J Ray; Martijn L T M Müller; Nicolaas I Bohnen
Journal:  Curr Behav Neurosci Rep       Date:  2020-10-09

5.  Walking exercise alters pedunculopontine nucleus connectivity in Parkinson's disease in a dose-dependent manner.

Authors:  Jiayue Cai; Aiping Liu; Yuheng Wang; Sun Nee Tan; Taylor Chomiak; Jacqueline Burt; Richard Camicioli; Bin Hu; Martin J McKeown; Fang Ba
Journal:  Front Neurosci       Date:  2022-08-09       Impact factor: 5.152

6.  Pedunculopontine Nucleus Dysconnectivity Correlates With Gait Impairment in Parkinson's Disease: An Exploratory Study.

Authors:  Stephen Joza; Richard Camicioli; W R Wayne Martin; Marguerite Wieler; Myrlene Gee; Fang Ba
Journal:  Front Aging Neurosci       Date:  2022-07-08       Impact factor: 5.702

7.  Functional Connectivity of Vermis Correlates with Future Gait Impairments in Parkinson's Disease.

Authors:  Baijayanta Maiti; Kerri S Rawson; Aaron B Tanenbaum; Jonathan M Koller; Abraham Z Snyder; Meghan C Campbell; Gammon M Earhart; Joel S Perlmutter
Journal:  Mov Disord       Date:  2021-06-10       Impact factor: 10.338

8.  Cholinergic Basal Forebrain Volumes Predict Gait Decline in Parkinson's Disease.

Authors:  Nicola J Ray; Lynn Rochester; Joanna Wilson; Alison J Yarnall; Chesney E Craig; Brook Galna; Sue Lord; Rosie Morris; Rachael A Lawson; Lisa Alcock; Gordon W Duncan; Tien K Khoo; John T O'Brien; David J Burn; John-Paul Taylor
Journal:  Mov Disord       Date:  2020-12-31       Impact factor: 10.338

9.  Gait variability is linked to the atrophy of the Nucleus Basalis of Meynert and is resistant to STN DBS in Parkinson's disease.

Authors:  Kevin B Wilkins; Jordan E Parker; Helen M Bronte-Stewart
Journal:  Neurobiol Dis       Date:  2020-10-10       Impact factor: 5.996

10.  Acceptability and Preliminary Results of Technology-Assisted Balance Training in Parkinson's Disease.

Authors:  Elvira Maranesi; Valentina Di Donna; Giuseppe Pelliccioni; Valentina Cameriere; Elisa Casoni; Renato Baldoni; Marco Benadduci; Nadia Rinaldi; Lorenzo Fantechi; Cinzia Giammarchi; Riccardo Luzi; Paolo Pelliccioni; Mirko Di Rosa; Pietro Scendoni; Giovanni Renato Riccardi; Roberta Bevilacqua
Journal:  Int J Environ Res Public Health       Date:  2022-02-24       Impact factor: 3.390

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.